A promyelocytic leukemia protein-thrombospondin-2 axis and the risk of relapse in neuroblastoma

Maria Dvorkina, Valentina Nieddu, Shalini Chakelam, Annalisa Pezzolo, Sandra Cantilena, Ana Paula Leite, Olesya Chayka, Tarik Regad, Angela Pistorio, Angela Rita Sementa, Alex Virasami, Jack Barton, Ximena Montano, Tanguy Lechertier, Nicola Brindle, Daniel Morgenstern, Morgane Lebras, Alan J. Burns, Nigel J. Saunders, Kairbaan Hodivala-DilkeLuigi Bagella, Hugues De The, John Anderson, Neil Sebire, Vito Pistoia, Arturo Sala, Paolo Salomoni

Research output: Contribution to journalArticle

Abstract

Purpose: Neuroblastoma is a childhood malignancy originating from the sympathetic nervous system with a complex biology, prone to metastasize and relapse. High-risk, metastatic cases are explained in part by amplification or mutation of oncogenes, such as MYCN and ALK, and loss of tumor suppressor genes in chromosome band 1p. However, it is fundamental to identify other pathways responsible for the large portion of neuroblastomas with no obvious molecular alterations. Experimental Design: Neuroblastoma cell lines were used for the assessment of tumor growth in vivo and in vitro. Protein expression in tissues and cells was assessed using immunofluorescence and IHC. The association of promyelocytic leukemia (PML) expression with neuroblastoma outcome and relapse was calculated using log-rank and Mann-Whitney tests, respectively. Gene expression was assessed using chip microarrays. Results: PML is detected in the developing and adult sympathetic nervous system, whereas it is not expressed or is low in metastatic neuroblastoma tumors. Reduced PML expression in patients with low-risk cancers, that is, localized and negative for the MYCN proto-oncogene, is strongly associated with tumor recurrence. PML-I, but not PML-IV, isoform suppresses angiogenesis via upregulation of thrombospondin-2 (TSP2), a key inhibitor of angiogenesis. Finally, PML-I and TSP2 expression inversely correlates with tumor angiogenesis and recurrence in localized neuroblastomas. Conclusions: Our work reveals a novel PML-I-TSP2 axis for the regulation of angiogenesis and cancer relapse, which could be used to identify patients with low-risk, localized tumors that might benefit from chemotherapy.

Original languageEnglish
Pages (from-to)3398-3409
Number of pages12
JournalClinical Cancer Research
Volume22
Issue number13
DOIs
Publication statusPublished - Jul 1 2016

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'A promyelocytic leukemia protein-thrombospondin-2 axis and the risk of relapse in neuroblastoma'. Together they form a unique fingerprint.

  • Cite this

    Dvorkina, M., Nieddu, V., Chakelam, S., Pezzolo, A., Cantilena, S., Leite, A. P., Chayka, O., Regad, T., Pistorio, A., Sementa, A. R., Virasami, A., Barton, J., Montano, X., Lechertier, T., Brindle, N., Morgenstern, D., Lebras, M., Burns, A. J., Saunders, N. J., ... Salomoni, P. (2016). A promyelocytic leukemia protein-thrombospondin-2 axis and the risk of relapse in neuroblastoma. Clinical Cancer Research, 22(13), 3398-3409. https://doi.org/10.1158/1078-0432.CCR-15-2081